tbuckley/cabot-search huggingface dataset:
Effect of Exogenous Surfactant (Calfactant) in Pediatric Acute Lung Injury: A Randomized Controlled Trial—Correction
Authors: Olivier Ameisen, James Garbutt, Henry Kranzler, Stephanie O'malley, David Gastfriend, Bernard Silverman, John Loewy, Elliot Ehrich, Helen Pettinati
Journal: JAMA (2005)
Chemistry and Toxicology of Quinoxaline, Organotin, Organofluorine, and Formamidine Acaricides
Authors: Charles O. Knowles
Journal: Environmental Health Perspectives (1976)

Quinoxaline, organotin, organofluorine, and formamidine compounds are among the newer pesticide chemicals used for acarine control. Included in these four classes are some of the most selective synthetic organic toxicants currently in the acaricide/insecticide arsenal. Oxythioquinox, Plictran (tricyclohexylhydroxytin), Nissol [2-fluoro-N-methyl-N-(1-naphthyl)acetamide], and chlordimeform are examples of quinoxaline, organotin, organofluorine, and formamidine acaricides, respectively. The chemistry and toxicology of these and related compounds are discussed.
Randomized phase III placebo-controlled trial of carboplatin/paclitaxel (CP) with or without the vascular-disrupting agent vadimezan (ASA404) in advanced non-small cell lung cancer (NSCLC).
Authors: P. Lara, J. Douillard, K. Nakagawa, J. Von Pawel, M. J. McKeage, I. Albert, G. Losonczy, M. Reck, D. S. Heo, X. Fan, A. Fandi, G. Scagliotti
Journal: Journal of Clinical Oncology (2011)

7502 Background: Vascular disruption of established tumor blood vessels is a unique anti-neoplastic strategy. In a randomized phase II trial in patients (pts) with advanced NSCLC, the vascular disrupting agent ASA404 (vadimezan) in combination with CP was found to improve several efficacy parameters including overall survival (OS). A global, double-blind, placebo-controlled phase III trial of frontline CP with or without ASA404 in advanced NSCLC was therefore conducted to validate these results. Methods: Pts with stage IIIB or IV NSCLC - stratified by sex and histology – with no prior systemic therapy for metastatic disease, good performance status (0 or 1), and acceptable end-organ function, were randomly assigned to Paclitaxel 200 mg/m2 and Carboplatin (AUC 6) +/- ASA404 (1,800 mg m2), given IV every 3 weeks for 6 cycles. Primary endpoint was OS. Secondary endpoints included response rate (RR) and progression-free survival (PFS). 1200 patients were required, based on a hazard ratio (HR) of 0.80, corresponding to a median OS of 9 vs. 11.24 months (CP+placebo vs. CP+ASA404, respectively). Results: A total of 1,299 pts were randomized. Baseline demographics were well balanced. Median age was 61 years, 62% were male, and 40% had PS=0. The trial was stopped for futility at interim analysis by the independent data safety monitoring committee. HR for OS was 1.01 (95% CI: 0.85, 1.19; p=0.535). Median OS was 13.4 (ASA404 + CP) vs. 12.7 months (placebo + CP). No difference in OS was seen in the histologic (squamous or non-squamous) and sex strata. Median PFS was 5 months in both arms (HR=1.04; p=0.7). Overall RR was comparable (25%) between the arms, as was the rate of adverse events (AEs). The most commonly reported AEs were neutropenia, alopecia, nausea, and fatigue. Grade 4 neutropenia (27% vs. 19%) and infusion site pain (10% vs. 0.5%) were more frequent in the ASA404 arm. Conclusions: Median OS was greater than 12.5 months with CP alone, exceeding a priori assumptions. The addition of ASA404 to CP, although generally well-tolerated, failed to improve efficacy in pts with advanced NSCLC.
Massachusetts Medical Society
Authors: John Figgis Jewett
Journal: New England Journal of Medicine (1958)

Obesity, with Exsanguination and ShockA twenty-seven-year-old gravida 1 died of hemorrhage five hours post partum while receiving her first and only unit of whole blood.Seen at eight weeks for her first prenatal visit the patient had a hemoglobin of 80 per cent (Sahli), gave a history of rheumatic fever in childhood and weighed 107.5 kg. (237 pounds), with a height of 160 cm. (5 feet, 3 inches). However, there was no evidence of organic heart disease then or later. She weighed 4.5 kg. (10 pounds) less at term and never developed any signs of toxemia. No subsequent hemoglobin . . .
INTERNATIONAL HEALTH EXHIBITION.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Beating heart versus conventional coronary artery bypass: Early versus late postoperative neurological complications Garrett K. Peel, Sotiris C. Stamou, Peter C. Hill, Ammar S. Bafi, Mercedes K. C. Dullum, Albert J. Pfister, Steven W. Boyce, Jorge M. Garcia, Paul J. Corso. Washington Hospital Center, Washington, DC
Journal: Journal of the American College of Cardiology (2001)
Abstract 3014: Microvascular Obstruction by Cardiac Magnetic Resonance is a Stronger Predictor of Outcomes than left Ventricular Ejection Fraction or End-Systolic Volume Index after Primary Coronary Intervention
Authors: Teruo Noguchi, Naoaki Yamada, Atushi Kawamura, Yoritaka Otsuka, Hiroshi Nonogi, Yoichi Goto
Journal: Circulation (2007)

Backgroud: Left ventricular (LV) end-systolic volume index (ESVI) and ejection fraction (EF) are predictor of long-term mortality following an acute myocardial infarction(AMI). However, interpretation of these parameters within 1 week of AMI is difficult due to myocardial stunning. We sought to correlate size of microvascular obstruction (MO), EF, and ESVI determined by cardiac magnetic resonance (CMR) to major cardiovascular events (MACE) after primary coronary intervention for ST-elevation MI (STEMI). Methods: CMR was performed in 94 consecutive STEMI patients within 1 week following AMI. The following indexes were calculated: size of MO/LV mass, infarct mass, EF, and ESVI. Patients were divided into two groups according to the size of MO: large MO group (MO/LV ≥ 0.1) and small MO group (MO/LV &lt; 0.1). A three-year clinical follow-up was recorded. Univariate and multivariate analyses were applied to identify predictors of MACE. Results: The mean LVEF and ESVI were 43 ± 13% and 49 ± 15 ml. The mean infarct mass was significantly greater in large MO group than that in small MO group (28 ± 15g vs. 19 ± 10g p&lt;0.01). Survival without MACE was significantly lower in patients with large MO group in comparison to those with small MO group (log-rank p&lt;0.001). Large MO (1.98 [95% CI 1.2–2.0], p=0.001), EF (0.91 [0.90 – 0.97], p=0.007), and ESVI (1.04 [1.01–1.06], p=0.01) were the only independent predictors of MACE. However, Large MO was a strongest predictor of MACE by multivariate analysis. Conclusions: EF, ESVI, and size of MO predict the future cardiac events. Size of MO measured by CMR, which is independent of stunning, was stronger predictors of MACE than either of the other two parameters.
Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: Does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes?
Authors: Victor A. Medina-Ravell, Gan-Xin Yan, Charles Antzelevitch, Ramarao S. Lankipalli, Napoleon A. Medina-Malpica, Otto A. Medina-Malpica, Christopher Droogan, Peter R. Kowey
Journal: Journal of the American College of Cardiology (2003)
O60 SAPPHIRE I: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN 631 TREATMENT-NAIVE ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1
Authors: J.J. Feld, K.V. Kowdley, E. Coakley, S. Sigal, D. Nelson, D. Crawford, O. Weiland, H. Aguilar, J. Xiong, B. DaSilva-Tillmann, L. Larsen, T. Podsadecki
Journal: Journal of Hepatology (2014)
Childhood myocarditis associated with Chlamydia trachomatis infection
Authors: J. T. Grayston
Journal: JAMA (1981)

Paired serum samples from six children with mild to fatal myocarditis have been studied in the microimmunofluorescence test for antibodies against<i>Chlamydia trachomatis</i>. Two patients with other known causes of myocarditis had no antibodies. The other four patients each had<i>C trachomatis</i>antibody. Two had high titer rises, and two with onset one to three months before the first serum sample was taken had level antibody titers. The study of serum from myocarditis patients was unplanned; they were part of a group of paired serum samples from children that had been submitted to the laboratory for viral diagnostic studies during a 16-month period. While the association of<i>C trachomatis</i>antibody with myocarditis was unexpected, it is consistent with the known etiologic role of<i>C psittaci</i>in myocarditis and the widening spectrum of systemic diseases caused by<i>C trachomatis</i>. Since<i>Chlamydia</i>can be treated with antibiotics, the possible etiologic association with myocarditis has important therapeutic ramifications. (<i>JAMA</i>1981;246:2823-2827)
THE FAILURE OF THE ERYSIPELAS TOXINS.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract IA23: Hematogenous metastasis of ovarian cancer: Rethinking mode of spread
Authors: Anil K. Sood
Journal: Cancer Research (2016)

Abstract Most patients with ovarian cancer present with widely metastatic disease. Although epithelial ovarian cancer was widely believed to metastasize via direct surface spread, the distribution of metastasis from the primary tumor is not completely random. Ovarian cancer has a clear predilection for metastasis to the omentum, but the underlying mechanisms involved in ovarian cancer spread are not well understood. We have used parabiosis model systems that demonstrate preferential hematogenous metastasis of ovarian cancer to the omentum. Our studies revealed that the ErbB3-neuregulin 1 (NRG1) axis is a dominant pathway responsible for hematogenous omental metastasis. Elevated levels of ErbB3 in ovarian cancer cells and NRG1 in the omentum allowed for tumor cell localization and growth in the omentum. Depletion of ErbB3 in ovarian cancer impaired omental metastasis. Our results highlight hematogenous metastasis as an important mode of ovarian cancer metastasis. These findings have implications for designing alternative strategies aimed at preventing and treating ovarian cancer metastasis. Citation Format: Anil K. Sood. Hematogenous metastasis of ovarian cancer: Rethinking mode of spread. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Metastasis; 2015 Nov 30-Dec 3; Austin, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(7 Suppl):Abstract nr IA23.
SATIRE
Authors: Preston J. Burnham
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
VIENNA
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The ethics of heart transplantation. A personal view
Authors: I. H. Page
Journal: JAMA (1969)

It seems a pity we have to spend so much time discussing and documenting not the scientific aspects of heart transplantation but the diverse problems related to it. However, a critical evaluation of these "happenings" can be most valuable, particularly in exposing for possible correction many of the unspoken and unexplored facets of medical practice and ethics. It is time to examine methods of scientific communication, criteria of death, confidentiality, rights of individuals, and the behavior of physicians, all quite aside from the value of cardiac transplantation as an experiment or a practical treatment. But I must warn you that I am no better prepared than anyone else to give definitive answers. My only claim to be heard is based on seniority and my belief that those who ignore the mistakes of the past are doomed to repeat them. I shall place my views at your disposal for consideration, not
Image analysis of lesions of the gallbladder and biliary system . Saint Louis University and St. John's Mercy Medical Center, St. Louis, MO
Journal: Hepatology (1995)

Background:The role of gastroesophageal devascularization (Sugiura-type procedures) for the treatment of variceal bleeding remains controversial. Although Japanese series reported favorable longterm results, the technique has not been widely accepted in the Western Hemisphere because of a high postoperative morbidity and mortality. The reasons for the different outcomes are unclear. In a multidisciplinary team approach we developed a therapeutic algorithm for patients with recurrent variceal bleeding.Study design:The Sugiura procedure was offered only to patients with well-preserved liver function (Child A or Child B cirrhosis without chronic ascites) who were not candidates for distal splenorenal shunt, transhepatic porto-systemic shunt, or liver transplantation.Results:Fifteen patients with recurrent variceal bleeding underwent a modified Sugiura procedure between September 1994 and September 1997. All but one patient (operative mortality 7%) are alive after a median followup of 4 years. Recurrent variceal bleeding developed in one patient; esophageal strictures, which were successfully treated by endoscopic dilatation, developed in three patients; and one patient experienced mild encephalopathy. Major complications were noted only in patients with impaired liver function (Child B cirrhosis) or when the modified Sugiura was performed in an emergency setting. The presence of cirrhosis or the cause of portal hypertension had no significant impact on the complication rate.Conclusions:This series was performed during the last decade when all modern therapeutic options for variceal bleeding were available. Our results indicate that the modified Sugiura procedure is an effective rescue therapy in patients who are not candidates for selective shunts, transhepatic porto-systemic shunt, or transplantation. Emergency settings and decreased liver function are associated with an increased morbidity.
A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction
Authors: E. M. Antman
Journal: JAMA (1992)

<h3>Objective.</h3> —To examine the temporal relationship between accumulating data from randomized control trials of treatments for myocardial infarction and the recommendations of clinical experts writing review articles and textbook chapters. <h3>Data Sources.</h3> —(1) MEDLINE search from 1966 to present; search terms used were<i>myocardial infarction, clinical trials, multicenter studies, double-blind method, meta-analysis</i>, and the text word "random:"; (2) references from pertinent articles and books; and (3) all editions of English-language general medical texts and manuals and review articles on treatment of myocardial infarction. <h3>Study Selection.</h3> —Randomized control trials of therapies for reducing the risk of total mortality in myocardial infarction (acute and secondary prevention). Review articles and textbook chapters dealing with the general clinical management of patients with myocardial infarction. <h3>Data Extraction.</h3> —Two authors read the material and recorded the results; disagreements were resolved by conference. <h3>Data Synthesis.</h3> —We used the technique of cumulative meta-analysis (performing a new meta-analysis when the results of a new clinical trial are published) and compared the results with the recommendations of the experts for various treatments for myocardial infarction. Discrepancies were detected between the meta-analytic patterns of effectiveness in the randomized trials and the recommendations of reviewers. Review articles often failed to mention important advances or exhibited delays in recommending effective preventive measures. In some cases, treatments that have no effect on mortality or are potentially harmful continued to be recommended by several clinical experts. <h3>Conclusions.</h3> —Finding and analyzing all therapeutic trials in a given field has become such a difficult and specialized task that the clinical experts called on to summarize the evidence in a timely fashion need access to better databases and new statistical techniques to assist them in this important task. (<i>JAMA</i>. 1992;268:240-248)
Crisis in drug testing. Results of CDC blind study
Authors: H. J. Hansen
Journal: JAMA (1985)

In response to questions about the reliability of the results of screening urine for drugs, we evaluated the performance of 13 laboratories, which serve a total of 262 methadone treatment facilities, by submitting prereferenced samples through the treatment facilities as patient samples (blind testing). Error rates for the 13 laboratories on samples containing barbiturates, amphetamines, methadone, cocaine, codeine, and morphine ranged from 11% to 94%, 19% to 100%, 0% to 33%, 0% to 100%, 0% to 100%, and 5% to 100%, respectively. Similarly, error rates on samples not containing these drugs (false-positives) ranged from 0% to 6%, 0% to 37% 0% to 66%, 0% to 6%, 0% to 7% and 0% to 10%, respectively. These blind tests indicate that (1) greater care is taken with known evaluation samples than with routine samples, (2) laboratories are often unable to detect drugs at concentrations called for by their contracts, and (3) the observed underreporting of drugs may threaten the treatment process. Drug treatment facilities should monitor the performance of their contract laboratories with quality-control samples, preferably through blind testing. (<i>JAMA</i>1985;253:2382-2387)
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer
Authors: Gordon Mosser
Journal: New England Journal of Medicine (2019)

Commonly, there is no designated leader, and communication is unreliable.These teams have a particularly high risk of dysfunction.The ineffectiveness of Ms. Clark's team ended once one member of the team stepped up and became the leader.A leader could have been designated earlier.Other team types are "template teams" and "true teams."They, too, have characteristic needs.Team effectiveness can be improved by identifying the team's type, reviewing the critical needs for teams of that type, and seeking to make sure that those needs are met.
THE LIGHT THAT NEVER WAS ON SEA AND LAND
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal